The results show that sequential treatment of BRAF targeted therapies with MCL-1 inhibitors (now in clinical trials) could overcome treatment resistance in melanoma patients.
This work was performed with financial support from the SU2C, the V foundation and the Ramón y Cajal programme.
Reference article:
Joan Montero et al. Destabilization of NOXA mRNA as a common resistance mechanism to targeted therapies. Nature Communications, 10, Article number: 5157 (2019).
